A Phase 4 interventional study of norepinephrine transporter polymorphism, in Attention Deficit Disorder With Hyperactivity, Methylphenidate and Pharmacogenetics, sponsored by Hallym University Medical Center. Completed at 1 site in Korea, Republic of. Open to participants aged 6 Years to 18 Years. Per ClinicalTrials.gov, last updated 2011-10-05.
Sponsored by Hallym University Medical Center · Phase 4, Interventional, and Treatment
The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that norepinephrine transporter polymorphism is associated with responses and adverse effects of OROS-methylphenidate in treatment of ADHD.
729 studies on the registry are indexed under Hyperkinesis; 25 are open to participants now.
This study's planned enrollment of 150 is above the median of 80 across 583 interventional studies indexed under Hyperkinesis.
Browse Hyperkinesis studies →Hallym University Medical Center is the lead sponsor of 52 studies on the registry; 5 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Genetic: norepinephrine transporter polymorphism,
OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism
Also known as: OROS methylphenidate (Concerta) monopharmacotherapy, dose : 18-54mg, duration : 8 weeks, genotyping : norepinephrine transporter (SLC6A2) polymorphism
Korean ADHD Rating scale-parent version (KARS)
Time frame: baseline,1,2,4,8 weeks
Barkely side effect rating scale
Time frame: 1,2,4,8weeks
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hallym University Medical Center